Residency · Residency · Urology

Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer

Overview

Intravesical therapy for non-muscle-invasive bladder cancer (NMIBC) primarily involves Bacillus Calmette-Guerin (BCG) immunotherapy, with well-established induction and maintenance schedules. Understanding the mechanism of action of BCG, appropriate timing and dosing, and management of BCG failure is essential. When BCG fails or is contraindicated, alternative treatments such as intravesical gemcitabine/docetaxel, valrubicin, and novel agents like nadofaragene firadenovec are considered.

Immediate Post-TURBT Intravesical Chemotherapy

A single perioperative instillation of intravesical chemotherapy is administered within 24 hours, ideally within 6 hours, after transurethral resection of bladder tumor (TURBT). Common agents used include gemcitabine at a dose of 2 grams in 100 mL and mitomycin C (MMC) at 40 mg in 40 mL. The rationale behind this immediate instillation is to destroy circulating tumor cells that may have been dislodged and implanted during the resection procedure. This approach reduces tumor recurrence by approximately 35% in low-risk tumors, representing a significant relative risk reduction. Gemcitabine is increasingly preferred over MMC due to its better tolerability, lower cost, and comparable efficacy, as demonstrated in the SWOG S0337 trial. However, this treatment is contraindicated in cases of known or suspected bladder perforation, extensive resection, or deep T1 disease because of the risk of extravasation and systemic absorption.

BCG Immunotherapy

Mechanism of Action

BCG is an attenuated strain of Mycobacterium bovis that is instilled directly into the bladder. Upon instillation, BCG attaches to the urothelium via fibronectin, initiating a complex immune response. This response involves both innate and adaptive immunity. The innate immune system activates macrophages and neutrophils, leading to granuloma formation. The adaptive immune response is predominantly Th1-mediated, involving CD4+ and CD8+ T cells as well as natural killer (NK) cells. Cytokines such as interleukin-2 (IL-2), interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) are released, resulting in both local and systemic anti-tumor immunity. Importantly, BCG does not act as a direct cytotoxic agent; rather, it exerts its effects through immune activation.

Strains

Several BCG strains are used worldwide, including Connaught, TICE (the most common in the United States), Tokyo-172, Danish, and Moreau. There is no convincing evidence that any one strain is superior to the others. A persistent global shortage of BCG has necessitated dose-reduction strategies and the exploration of alternative therapies.

Induction Schedule

The standard induction protocol, based on the SWOG regimen, consists of six weekly instillations beginning 2 to 4 weeks after TURBT. This delay allows for adequate wound healing and reduces the risk of systemic absorption. Each instillation involves retaining a 50 mL suspension in the bladder for 1 to 2 hours before voiding. Patients should be well hydrated and catheterization should be avoided if possible. The first follow-up cystoscopy and cytology are typically performed three months after induction to assess response.

Maintenance Schedule (SWOG Protocol — Lamm)

Maintenance therapy involves three weekly instillations at months 3, 6, 12, 18, 24, 30, and 36 following induction. The SWOG 8507 trial demonstrated that maintenance BCG significantly improves recurrence and progression outcomes compared to induction alone. Therefore, a full three-year maintenance course is recommended for patients with high-risk NMIBC. In the context of BCG shortages, reduced-dose maintenance (one-third dose) or shortened schedules may be considered. For intermediate-risk patients, one year of maintenance therapy may suffice.

BCG Administration Pearls

BCG should not be administered in the presence of active urinary tract infection (UTI), traumatic catheterization, gross hematuria, within two weeks of TURBT, or in immunosuppressed patients due to the risk of systemic infection. Patients are advised to limit fluid intake for four hours prior to instillation and to retain the instillation for 1 to 2 hours, repositioning periodically to ensure even distribution. After voiding, patients should sit down and add bleach to the toilet for six hours to prevent environmental contamination. Sexual contact should be avoided for 48 hours following instillation.

BCG Side Effects and Management

Common (Expected)

The most frequent side effect, termed "BCG-itis," includes symptoms such as dysuria, urinary frequency, urgency, and low-grade fever, occurring in 60-80% of patients. These symptoms are typically self-limiting and resolve within 48 hours. Management involves supportive care with nonsteroidal anti-inflammatory drugs (NSAIDs), anticholinergics, and phenazopyridine.

Moderate

Moderate side effects include prolonged high-grade fever exceeding 38.5°C for more than 48 hours and symptomatic granulomatous prostatitis. In such cases, BCG therapy is held, and treatment with isoniazid plus a fluoroquinolone for three months may be initiated. After resolution, BCG can potentially be resumed at a reduced dose.

Severe (Rare but Serious)

Severe complications include BCG sepsis, characterized by high fever, hemodynamic instability, and multi-organ dysfunction. Risk factors for BCG sepsis include traumatic catheterization, concurrent UTI, and recent biopsy. Treatment requires triple anti-tuberculosis therapy (isoniazid, rifampin, and ethambutol) combined with high-dose steroids, and all further BCG therapy must be discontinued permanently. Other severe complications such as granulomatous hepatitis, pneumonitis, epididymo-orchitis, and septic arthritis also necessitate anti-tuberculosis therapy and permanent cessation of BCG.

BCG Failure Definitions

BCG-Refractory

BCG-refractory disease is defined as persistent high-grade tumor at six months despite adequate BCG therapy, which includes induction plus maintenance or re-induction. Additionally, the presence of T1 disease at three months after induction also qualifies as refractory.

BCG-Relapsing

BCG-relapsing disease refers to the recurrence of high-grade tumor after achieving an initial complete response (CR) to BCG. Early relapse, occurring less than six months after BCG, carries a worse prognosis, while relapse between six and twelve months is intermediate. Very late relapse beyond twelve months may still respond to re-induction therapy.

BCG-Unresponsive (FDA/AUA Definition)

The BCG-unresponsive category includes patients who are either BCG-refractory or who relapse within twelve months after receiving adequate BCG therapy, defined as at least five of six induction doses plus two of three maintenance doses or re-induction. This group has less than a 15% durable response rate to further BCG and is eligible for clinical trials or novel agents targeting BCG-unresponsive disease.

BCG-Intolerant

BCG-intolerant patients are those unable to complete BCG therapy due to toxicity. This is distinct from BCG failure, as their disease may still be responsive to BCG if therapy could be tolerated.

Alternatives to BCG

Intravesical Chemotherapy

Gemcitabine + Docetaxel (Gem/Doce)

A sequential alternating instillation protocol involves administering 1 gram of gemcitabine intravesically followed by 37.5 mg of docetaxel, each retained for one hour weekly for six weeks as induction. Maintenance therapy consists of monthly instillations for 12 to 24 months. Retrospective data show initial complete response rates of 60-70% with approximately 50% recurrence-free survival at two years. This regimen is increasingly used for BCG-unresponsive disease or during BCG shortages due to its good tolerability and low systemic absorption.

Mitomycin C

Mitomycin C is an alkylating agent with direct cytotoxic effects. It is administered as 40 mg in 40 mL instilled for 1 to 2 hours weekly for 6 to 8 weeks during induction. Optimization strategies include alkalinizing the urine, reducing instillation volume, and minimizing voiding prior to treatment. Although less effective than BCG for high-risk disease, MMC remains useful for intermediate-risk patients. Side effects include chemical cystitis, skin rash if contact occurs, and bladder contracture with prolonged use.

Valrubicin (Valstar)

Valrubicin is an anthracycline derivative approved by the FDA for BCG-refractory carcinoma in situ (CIS) in patients who are not candidates for cystectomy. Its efficacy is limited, with about an 18% durable response rate, and it is rarely used now given the availability of better alternatives.

Novel Agents for BCG-Unresponsive Disease

Nadofaragene Firadenovec (Adstiladrin)

Nadofaragene firadenovec is a non-replicating adenovirus vector that delivers the interferon-alpha-2b gene to urothelial cells, inducing local interferon production. Instilled intravesically, it was FDA-approved in 2022 for BCG-unresponsive NMIBC, including CIS with or without papillary disease. Phase 3 trials demonstrated a 53% complete response rate at three months and approximately 24% durable response at 12 months. It is administered every three months and is generally well tolerated, with urinary symptoms being the most common side effects.

Pembrolizumab (Keytruda)

Pembrolizumab is a systemic anti-PD-1 checkpoint inhibitor. The KEYNOTE-057 trial showed a 41% complete response rate in BCG-unresponsive CIS at three months. It is FDA-approved for patients with BCG-unresponsive CIS who are ineligible for or decline cystectomy. Immune-related adverse events include thyroid dysfunction, colitis, pneumonitis, and skin toxicity. Pembrolizumab is administered intravenously every three weeks for up to 24 months.

Nogapendekin Alfa Inbakicept (Anktiva/N-803)

Nogapendekin alfa inbakicept is an interleukin-15 receptor agonist combined with intravesical BCG. Approved by the FDA in 2024 for BCG-unresponsive CIS, the QUILT 3.032 trial reported a 62% complete response rate with approximately 50% sustained at 12 months. It is administered intravesically and subcutaneously alongside BCG.

TAR-200 (Gemcitabine Intravesical Drug Delivery System)

TAR-200 is a pretzel-shaped device placed in the bladder that releases gemcitabine continuously over three weeks. It is currently under investigation in the SunRISe trials for BCG-unresponsive disease. Early results are promising, suggesting that continuous drug exposure may improve efficacy.

Role of Early Radical Cystectomy

Radical cystectomy should be considered over bladder-sparing approaches in patients with BCG-unresponsive high-grade T1 disease who have adverse features such as variant histology (micropapillary, nested, plasmacytoid), lymphovascular invasion, extensive or multifocal T1 disease, prostatic urethral involvement, or associated CIS. Multiple BCG failures and patient fitness and willingness for surgery also influence this decision. Delaying cystectomy beyond the BCG-unresponsive state may worsen survival outcomes. However, not all BCG-unresponsive patients require immediate cystectomy, as novel agents offer bladder-sparing potential with acceptable complete response rates. Shared decision-making based on risk factors, patient preferences, and close response monitoring is essential.

<image>A timeline diagram showing the BCG treatment schedule for high-risk NMIBC: TURBT at week 0, 2-4 week healing period, 6-week induction course (weekly instillations shown as numbered markers), 3-month cystoscopy/cytology evaluation, then SWOG maintenance schedule with 3 weekly instillations at months 3, 6, 12, 18, 24, 30, and 36. Decision points are marked at each follow-up cystoscopy showing outcomes: complete response (continue maintenance), persistent disease (re-evaluate), and BCG failure (switch to alternative or cystectomy). Color-coded timeline with clinical milestones.</image>

<image>A decision algorithm for managing BCG failure in NMIBC. Starting with BCG failure classification (refractory, relapsing early vs. late, unresponsive, intolerant), branches lead to treatment options: late relapse may receive BCG re-induction; BCG-unresponsive branches to either radical cystectomy (fit, high-risk features) or bladder-sparing options (nadofaragene, pembrolizumab, N-803+BCG, gem/doce, clinical trials). Each treatment option includes response rates from key trials. Clean clinical flowchart format with trial data annotations.</image>

<image>A mechanism of action diagram for BCG immunotherapy showing the sequential steps: 1) BCG instillation into bladder lumen, 2) attachment to urothelium via fibronectin, 3) internalization by urothelial cells and macrophages, 4) antigen presentation and Th1 immune response activation, 5) recruitment of CD4+ T cells, CD8+ T cells, NK cells, and neutrophils to the urothelium, 6) tumor cell killing through cytokine release (IL-2, IFN-gamma, TNF-alpha) and direct cytotoxicity. Immunology illustration showing cellular interactions at the bladder wall. Medical illustration style.</image>

Clinical Pearls

BCG remains the gold standard treatment for high-risk NMIBC and is the only intravesical agent proven to reduce disease progression and improve survival. It is critical to avoid instilling BCG after traumatic catheterization or within two weeks of TURBT or biopsy due to the risk of systemic absorption and potentially fatal BCG sepsis. Maintenance therapy following the SWOG schedule for three years is essential, as induction alone is insufficient for high-risk disease. The definition of BCG-unresponsive disease requires verification of adequate prior BCG exposure before labeling a patient as such. Gemcitabine/docetaxel has emerged as the most commonly used alternative regimen during BCG shortages or after BCG failure, demonstrating promising response rates. A single immediate post-TURBT instillation of gemcitabine represents one of the highest-value, lowest-cost interventions in urology and should not be omitted in eligible low-risk patients. Patients with BCG-unresponsive high-grade T1 disease exhibiting adverse features such as lymphovascular invasion, variant histology, or multifocality should be strongly counseled toward early radical cystectomy rather than further bladder-sparing attempts.

References

• Lamm DL, et al. Maintenance BCG immunotherapy for recurrent Ta, T1, and CIS TCC of the bladder: a randomized SWOG study. J Urol. 2000;163(4):1124-1129
• Boorjian SA, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2021;39(22):2514-2522
• de Wit R, et al. Pembrolizumab for BCG-unresponsive CIS of the bladder (KEYNOTE-057). J Clin Oncol. 2022;40(4):401-411
• Steinberg RL, et al. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of NMIBC. Bladder Cancer. 2015;1(1):65-72
• Chang SS, et al. AUA/SUO Guideline: Diagnosis and Treatment of NMIBC, 2020 Amendment
• NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2024

Read this lecture as Markdown